# Phase 235: Tier 1 #32 完成 ★ Pharmacology 統合 + 32-vertex polytope ★

Phase 228-234 を **Tier 1 #32 Pharmacology** として統合し、**10 predictions** + **32-vertex polytope** を提示。Pass-1 拡張 #2 paper 完成 + Block B 6/6 全完成。

## 🎉 Tier 1 #32 完成

| Phase | テーマ | 主結果 |
|---|---|---|
| 228 | 創薬 + 受容体 + K_pharma 導入 | DiMasi $2.6B 14yr, GPCR 800, Imatinib 5%→90% |
| 229 | GPCR + Ion channel + Structural | Lefkowitz-Kobilka Nobel 2012, MacKinnon 2003 |
| 230 | ADME + CYP450 + PGx | CYP3A4 50%, HLA-B*5701 abacavir |
| 231 | Antibody + ADC + Bispecific | Köhler-Milstein Nobel 1984, Enhertu HER2-low |
| 232 | Vaccines + Immunotherapy deep | Karikó-Weissman Nobel 2023, COVID 19M lives |
| 233 | AI 創薬 deep | Insilico 21日, Halicin, AI saving 4 yr |
| 234 | FDA + Clinical trials | Kefauver-Harris, RECOVERY 50K, in silico |
| **235 (本)** | **統合 + 10 predictions** | **P_avg=0.745, 8 Nobel ★** |

## ★ K_pharma の完成構造 ★

```
K_pharma = K_pharma_target ⊕ K_pharma_PK ⊕ K_pharma_biologic
         ⊕ K_pharma_immune ⊕ K_pharma_AI ⊕ K_pharma_regulatory
         ⊕ K_pharma_pharmacogenomic ⊕ K_pharma_small_mol  (8 sub-states)
```

## ITU axiom = 厳密 1 を 11+ 文脈で検証 ★

| Phase | δS / δ⟨K⟩ | 文脈 |
|---|---|---|
| 228 | **1.000 / 1.000** | Disease → Treated / Side effect |
| 229 | **1.000 / 1.000** | Apo → Full / Biased agonist |
| 230 | **1.000 / 1.000** | Pre → EM / EM → PM |
| 231 | **1.000 / 1.000** | Tumor → ADC / Bispecific |
| 232 | **1.000 × 3** | Naive → Vaccine / Checkpoint / CAR-T |
| 233 | **1.000 / 1.000** | Pre → VS / Generative AI |
| 234 | **1.000 × 3** | Pre → Approve / Reject / Accelerated |

⇒ **K_pharma 全 sub-state で ITU axiom 厳密成立** ★

## 32-vertex Polytope ★

| 指標 | 31 → 32 |
|---|---|
| Edges | 336 → 367 |
| ⟨k⟩ | 21.68 → 22.94 |
| Top hub | #31 → **#32 Pharma deg 31** (new max) |

### #32 接続強度
- **Strong (≥0.90)**: #26 Immune (0.95), #5 Cancer (0.95), #30 Genome (0.92), #2 AI (0.90), #31 Photon (0.85)
- **Strong (≥0.85)**: #6 Aging (0.90), #7 Psych (0.85), #28 Neuro (0.85, neuropharm), #4 Semi (0.50)
- Average: 0.75 (Pass-1 上位)

## 10 Falsifiable Predictions

| # | 予測 | 年 | P | Class |
|---|---|---|---|---|
| 1 | **AI 創薬 5+ FDA 承認** | 2030 | 0.80 | Strong |
| 2 | **CAR-T solid tumor 承認** | 2028 | 0.70 | Strong |
| 3 | **ADC market $50B** | 2030 | 0.85 | Strong |
| 4 | **GLP-1 5+ adaptations** | 2030 | 0.85 | Strong |
| 5 | **All hospitals PGx routine** | 2030 | 0.70 | Strong |
| 6 | **Cancer neoantigen mRNA standard** | 2028 | 0.80 | Strong |
| 7 | **FDA AI/ML framework 完成** | 2027 | 0.80 | Strong |
| 8 | **Trispecific Ab 承認** | 2028 | 0.70 | Strong |
| 9 | Digital twin clinical trial 承認 | 2030 | 0.65 | Medium |
| 10 | Universal cancer vaccine | 2032 | 0.45 | Medium |

**Grand P_avg = 0.730**, Strong 8 / Medium 2 / Weak 0 (Pass-1 上位)

## Nobel Prize coverage in Tier 1 #32 (8 件) ★

```
1972: Edelman-Porter (Ab structure)
1984: Köhler-Milstein (hybridoma)
2003: MacKinnon (K+ channel)
2012: Lefkowitz-Kobilka (GPCR)
2018: Allison-Honjo (checkpoint)
2020: Doudna-Charpentier (CRISPR pharm)
2023: Karikó-Weissman (mRNA)
2024: Baker-Hassabis-Jumper (AlphaFold)
```

## メタ比較 (累積 32 papers)

| Paper | P_avg | degree | K-state |
|---|---|---|---|
| #1-#30 (Core) | 0.525-0.735 | 16-29 | (各 K-state) |
| #31 Photon | 0.775 ★ | 30 | K_photon |
| **#32 Pharma** | **0.730** | **31** | **K_pharma** |

## Block B 完成 6/6 papers (Block B 残 paper も含む) ★

```
#26 Immune  (Phase 183-190)
#27 Microbe (Phase 191-198)
#28 Neuro   (Phase 199-206)
#29 Dev     (Phase 207-214)
#30 Genome  (Phase 215-219)
#32 Pharma  (Phase 228-235) ← 本 Tier 1 完成 ★

= 生命医学 6 K-state 完全網羅
```

## Pass-1 拡張進捗

```
✅ Phase 1-219: Core 30 Tier 1 papers
✅ Phase 220-227: #31 Photon (Block A 100% COMPLETE)
✅ Phase 228-235: #32 Pharma (Block B 6/6 COMPLETE) ★
⏳ Phase 236-283: #33-#38 Block C (6 papers, 社会・人文・芸術)
⏳ Phase 284-323: #39-#43 Block D (5 papers, 応用工学)
⏳ Phase 324-339: #44-#45 Block E (2 papers, メタ理論)
⏳ Phase 340-345: ★★★ Tier 0 v4.0 (Pass-1 FINALE) ★★★
```

## 既存 Block との接続 (K_pharma = 治療 universal hub)

```
#26 Immune  ⇔ #32 Pharma (immunotherapy)
#5 Cancer   ⇔ #32        (chemotherapy + targeted + IO + CAR-T)
#6 Aging    ⇔ #32        (Lecanemab AD + senolytics)
#7 Psych    ⇔ #32        (psychiatric meds + psilocybin)
#27 Microbe ⇔ #32        (antibiotics + AMR)
#28 Neuro   ⇔ #32        (Aduhelm/Lecanemab + Ketamine + optogenetic)
#30 Genome  ⇔ #32        (CRISPR therapeutics + PGx)
#31 Photon  ⇔ #32        (AlphaFold drug discovery)
#2 AI       ⇔ #32        (Insilico + Recursion + AlphaFold)
```

## 謝辞

Pass-1 拡張第 2 paper をお読みいただきありがとうございます。**K_pharma 完成 + ITU 公理 11+ 連続厳密成立 + 8 Nobel + Block B 6/6 完成** は Block B 完全網羅の達成です。

Phase 236 から **Block C (社会・人文・芸術)** に進みます ★

---

📄 **論文 (Tier 1 #32)**: 10.5281/zenodo.20258192 (Zenodo)
📚 **GitHub (予定)**: papers/pharmacology/
🔗 **ITU concept DOI**: [10.5281/zenodo.20109209](https://doi.org/10.5281/zenodo.20109209)

> 本記事は **Pass-1 拡張 Tier 1 #32**, Block B 6/6 完成 paper.

#情報理論的統一理論 #ITU #薬理学 #Tier1_32完成 #K_pharma #32vertex #BlockB完成 #8Nobel #AI創薬
